UMUC3 |
Cell viability assay |
0.1 or 0.4 μg/ml |
24, 48, and 73 h |
Curcumin alone, added at a concentration from 0.1 to 0.4 μg/ml, did not alter cell growth of RT112 cells, slightly reduced UMUC3 cell growth at 0.4 μg/ml, and only moderately suppressed growth of TCCSUP at 0.2 and 0.5 μg/ml, each compared to respective controls |
30984278 |
RT112 |
Cell viability assay |
0.1 or 0.4 μg/ml |
24, 48, and 72 h |
Curcumin alone, added at a concentration from 0.1 to 0.4 μg/ml, did not alter cell growth of RT112 cells, slightly reduced UMUC3 cell growth at 0.4 μg/ml, and only moderately suppressed growth of TCCSUP at 0.2 and 0.4 μg/ml, each compared to respective controls |
30984278 |
U87 |
Cell viability assay |
0, 10, 20, 30, 40, and 50 µM/L |
24 hours |
At concentrations higher than 20 µM/L, cell viabilities steeply declined |
31062527 |
HEL cells |
Cell viability assay |
0-30 µmol/L |
24/48 hours |
The viability of the HEL cells exposed to curcumin was significantly lower compared to control cells even at low concentrations. |
31033209 |
TCCSUP |
Cell viability assay |
0.1 or 0.4 μg/ml |
24, 48, and 74 h |
Curcumin alone, added at a concentration from 0.1 to 0.4 μg/ml, did not alter cell growth of RT112 cells, slightly reduced UMUC3 cell growth at 0.4 μg/ml, and only moderately suppressed growth of TCCSUP at 0.2 and 0.6 μg/ml, each compared to respective controls |
30984278 |
A549 |
Apoptosis assay |
2.1 to 4.2 uM |
24 hrs |
Induction of apoptosis in human A549 cells at 2.1 to 4.2 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry |
26891099 |
A549/CDDP |
Apoptosis assay |
0.6 to 1.2 uM |
24 hrs |
Induction of apoptosis in human A549/CDDP cells at 0.6 to 1.2 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry |
26891099 |
SH-SY5Y |
Function assay |
1 to 5 uM |
24 hrs |
Antioxidant activity against t-BHP-induced oxidative stress in human SH-SY5Y cells assessed as inhibition of ROS production at 1 to 5 uM after 24 hrs by DCFH-DA probe based flow cytometric analysis |
27856236 |
K562 |
Function assay |
20 to 30 uM |
48 hrs |
Down regulation of p-gp expression in doxorubicin resistant human K562 cells at 20 to 30 uM measured after 48 hrs by Western blot method |
27908756 |
K562 |
Cell cycle assay |
20 uM |
48 hrs |
Cell cycle arrest in doxorubicin resistant human K562 cells assessed as decrease in G0/G1 phase at 20 uM measured after 48 hrs by propidium iodide staining based flow cytometry |
27908756 |
K562 |
Cell cycle assay |
20 uM |
48 hrs |
Cell cycle arrest in doxorubicin resistant human K562 cells assessed as increase in G2/M phase at 20 uM measured after 48 hrs by propidium iodide staining based flow cytometry |
27908756 |
K562 |
Function assay |
20 to 40 uM |
48 hrs |
Up regulation of p53 expression in doxorubicin resistant human K562 cells at 20 to 40 uM measured after 48 hrs by Western blot method |
27908756 |
K562 |
Cell cycle assay |
20 uM |
48 hrs |
Cell cycle arrest in doxorubicin resistant human K562 cells assessed as decrease in S phase at 20 uM measured after 48 hrs by propidium iodide staining based flow cytometry |
27908756 |
K562 |
Cell cycle assay |
30 to 40 uM |
48 hrs |
Cell cycle arrest in doxorubicin resistant human K562 cells assessed as accumulation at G0/G1 phase at 30 to 40 uM measured after 48 hrs by propidium iodide staining based flow cytometry |
27908756 |
K562 |
Cell cycle assay |
30 to 40 uM |
48 hrs |
Cell cycle arrest in doxorubicin resistant human K562 cells assessed as decrease in G2/M phase at 30 to 40 uM measured after 48 hrs by propidium iodide staining based flow cytometry |
27908756 |
K562 |
Function assay |
20 to 40 uM |
48 hrs |
Down regulation of cyclin B1 expression in doxorubicin resistant human K562 cells at 20 to 40 uM measured after 48 hrs by Western blot method |
27908756 |
K562 |
Apoptosis assay |
20 to 40 uM |
48 hrs |
Induction of apoptosis in doxorubicin resistant human K562 cells decrease in pro-caspase 3 level at 20 to 40 uM measured after 48 hrs by Western blot method |
27908756 |
K562 |
Apoptosis assay |
20 to 40 uM |
48 hrs |
Induction of apoptosis in doxorubicin resistant human K562 cells assessed as increase in PARP-1 cleavage at 20 to 40 uM measured after 48 hrs by Western blot method |
27908756 |
PC12 |
Neuroprotective assay |
0.1 to 10 uM |
24 hrs |
Neuroprotective activity against H202-induced toxicity in rat PC12 cells assessed as increase in cell viability at 0.1 to 10 uM after 24 hrs by MTT assay |
28302511 |
PC12 |
Neuroprotective assay |
0.1 to 10 uM |
24 hrs |
Neuroprotective activity against Abeta42-induced toxicity in rat PC12 cells assessed as increase in cell viability at 0.1 to 10 uM after 24 hrs by MTT assay |
28302511 |
cells at |
Growth inhibition assay |
30 uM |
48 hrs |
Growth inhibition of human Hep3B cells at 30 uM after 48 hrs by MTT assay |
28342400 |
HepG2 |
Function assay |
5 uM |
24 hrs |
Activation of Nrf2 in human HepG2 cells assessed as cytoprotection against t-BHP-induced oxidative cell death at 5 uM incubated for 24 hrs followed by compound removal with subsequent incubation with 900 uM of t-BHP for 6 hrs by MTT assay |
28399452 |
HCT116 |
Function assay |
500 uM |
48 hrs |
Induction of glutathione oxidation in human HCT116 cells assessed as increase in GSSG/GSH ratio at 500 uM in presence of NADPH after 48 hrs by Ellman's method |
28716495 |
BGC823 |
Growth inhibition assay |
20 uM |
72 hrs |
Growth inhibition of human BGC823 cells at 20 uM after 72 hrs by MTT assay |
28881286 |
SGC7901 |
Growth inhibition assay |
20 uM |
72 hrs |
Growth inhibition of human SGC7901 cells at 20 uM after 72 hrs by MTT assay |
28881286 |
MFC |
Growth inhibition assay |
20 uM |
72 hrs |
Growth inhibition of MFC cells at 20 uM after 72 hrs by MTT assay |
28881286 |
NCI-H460 |
Growth inhibition assay |
5 to 10 uM |
24 to 72 hrs |
Growth inhibition of human NCI-H460 cells assessed as reduction in cell viability at 5 to 10 uM incubated for 24 to 72 hrs by MTT assay |
29288946 |
NCI-H460 |
Growth inhibition assay |
20 uM |
18 hrs |
Anti-growth activity against human NCI-H460 cells assessed as reduction in colony formation at 20 uM after 18 hrs by crystal violet-based colony forming assay |
29288946 |
NCI-H460 |
Antimigratory assay |
20 uM |
48 hrs |
Anti-migratory activity against human NCI-H460 cells at 20 uM incubated for 48 hrs by wound healing assay |
29288946 |
NCI-H460 |
Apoptosis assay |
15 mg/kg |
15 days |
Induction of apoptosis in tumor of human NCI-H460 cells xenografted in BALB/C nu nude mouse assessed as downregulation of bcl2 expression at 15 mg/kg, ip administered everyday for 15 days by Western blot analysis |
29288946 |
HT22 |
Cytoprotection assay |
1 uM |
24 hrs |
Cytoprotection against glutamate-induced apoptosis in mouse HT22 cells assessed as decrease in Bax/Bcl2 ratio at 1 uM after 24 hrs by RT-PCR method |
30031653 |
HT22 |
Cytoprotection assay |
1 uM |
24 hrs |
Cytoprotection against glutamate-induced oxidative stress in mouse HT22 cells assessed as decrease in iNOS mRNA level at 1 uM after 24 hrs by RT-PCR method |
30031653 |
HT22 |
Cytoprotection assay |
1 uM |
24 hrs |
Cytoprotection against glutamate-induced excitotoxicity in mouse HT22 cells assessed as increase in cell viability at 1 uM after 24 hrs by optical microscopic assay |
30031653 |
HT22 |
Cytoprotection assay |
1 uM |
24 hrs |
Cytoprotection against glutamate-induced excitotoxicity in mouse HT22 cells assessed as decrease in glutamate-induced cell cycle arrest at sub-G1 phase at 1 uM after 24 hrs by propidium iodide staining based flow cytometry |
30031653 |
HT22 |
Cytoprotection assay |
1 uM |
24 hrs |
Cytoprotection against glutamate-induced excitotoxicity in mouse HT22 cells assessed as increase in cell proliferation at 1 uM after 24 hrs by MTT assay |
30031653 |
RAW264.7 |
Function assay |
10 uM |
0.5 hrs |
Inhibition of MAPK/NFkappaB in ICR mouse RAW264.7 cells assessed as reduction in LPS-induced TNFalpha production at 10 uM pretreated for 0.5 hrs followed by LPS challenge and measured after 24 hrs by ELISA relative to control |
30780088 |
RAW264.7 |
Function assay |
10 uM |
0.5 hrs |
Inhibition of LPS-induced p38 MAPK phosphorylation in ICR mouse RAW264.7 cells at 10 uM preincubated for 0.5 hrs followed by LPS challenge and measured after 30 mins by immunoblotting analysis |
30780088 |
RAW264.7 |
Function assay |
10 uM |
0.5 hrs |
Inhibition of LPS-induced ERK phosphorylation in ICR mouse RAW264.7 cells at 10 uM preincubated for 0.5 hrs followed by LPS challenge and measured after 30 mins by immunoblotting analysis |
30780088 |
RAW264.7 |
Function assay |
10 uM |
0.5 hrs |
Inhibition of NFkappaB/MAPK signaling in LPS-induced mouse RAW264.7 cells assessed as down regulation of IkappaB expression at 10 uM preincubated for 0.5 hrs followed by LPS-challenge and measured after 30 mins by immunoblotting analysis |
30780088 |
RAW264.7 |
Function assay |
10 uM |
0.5 hrs |
Inhibition of MAPK/NFkappaB in ICR mouse RAW264.7 cells assessed as reduction in LPS-induced IL6 production at 10 uM pretreated for 0.5 hrs followed by LPS challenge and measured after 24 hrs by ELISA relative to control |
30780088 |
Raw246.7 |
Cell viability assay |
1, 5, 10, 50, 100, 200, and 500 g/mL |
|
|
31007701 |
RAW264.7 |
Antiinflammatory assay |
20 uM |
|
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production at 20 uM by ELISA |
28284806 |
RAW264.7 |
Antiinflammatory assay |
20 uM |
|
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production at 20 uM by ELISA |
28284806 |
3T3L1 |
Function assay |
10 ng/ml |
|
Inhibition of TNFalpha-induced NFkappaB activation (unknown origin) expressed in mouse 3T3L1 cells at 10 ng/ml by luciferase reporter gene assay |
ChEMBL |
KBM5 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human KBM5 cells after 72 hrs by MTT assay, IC50 = 3.84 μM. |
24280069 |
Jurkat |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay, IC50 = 4.29 μM. |
24280069 |
U266 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human U266 cells after 72 hrs by MTT assay, IC50 = 7.57 μM. |
24280069 |
A549 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 17.3 μM. |
24280069 |
MCF7 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay, IC50 = 32.2 μM. |
26174555 |
SKOV3 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human SKOV3 cells after 24 hrs by MTT assay, IC50 = 43.63 μM. |
26174555 |
CT26 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse CT26 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 7.7 μM. |
26318057 |
SW620 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 12.52 μM. |
26318057 |
SGC7901 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human SGC7901 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 24.41 μM. |
26318057 |
GES-1 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human GES-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 27.89 μM. |
26318057 |
MGC803 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human MGC803 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 31.39 μM. |
26318057 |
U2OS |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human U2OS cells expressing wild-type p53 after 48 hrs by crystal violet-staining based spectrophotometric assay, EC50 = 22.8 μM. |
26606246 |
Saos2 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human Saos2 cells expressing p53 mutant after 48 hrs by crystal violet-staining based spectrophotometric assay, EC50 = 28.1 μM. |
26606246 |
U2OS |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human U2OS cells expressing wild-type p53 after 24 hrs by crystal violet-staining based spectrophotometric assay, EC50 = 34.4 μM. |
26606246 |
Saos2 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human Saos2 cells expressing p53 mutant after 24 hrs by crystal violet-staining based spectrophotometric assay, EC50 = 48.6 μM. |
26606246 |
T98G |
Antiproliferative assay |
|
24 hrs |
Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay, IC50 = 10 μM. |
26631318 |
T98G |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human T98G cells assessed as cell viability after 72 hrs by MTT assay, IC50 = 25 μM. |
26631318 |
SH-SY5Y |
Antiproliferative assay |
|
48 hrs |
Antiproliferative activity against human SH-SY5Y cells assessed as cell viability after 48 hrs, IC50 = 16.1 μM. |
26705144 |
HeLa |
Antiproliferative assay |
|
48 hrs |
Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs, IC50 = 21.8 μM. |
26705144 |
HeLa |
Cell cycle assay |
|
16 hrs |
Cell cycle arrest in human HeLa cells assessed as accumulation at G1 phase at IC50 to 2 times IC50 after 16 hrs by FACS analysis |
26705144 |
HuH7 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human HuH7 cells after 48 hrs by MTT assay, IC50 = 48 μM. |
26783179 |
HeLa |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability after 3 days by WST-1 assay, IC50 = 12.11 μM. |
26827161 |
LNCAP |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against human LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 assay, IC50 = 13.61 μM. |
26827161 |
PC3 |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against human PC3 cells assessed as inhibition of cell viability after 3 days by WST-1 assay, IC50 = 25.43 μM. |
26827161 |
DU145 |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against human DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 assay, IC50 = 26.23 μM. |
26827161 |
RAW264.7 |
Antiinflammatory assay |
|
24 hrs |
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay, IC50 = 19.1 μM. |
26841168 |
BV2 |
Function assay |
|
24 hrs |
Inhibition of LPS-induced NO production in mouse BV2 cells assessed as reduction in nitrite level pretreated for 24 hrs before LPS treatment for additional 24 hrs by Griess reaction method, IC50 = 0.52 μM. |
26859776 |
A549/CDDP |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay, IC50 = 32.39 μM. |
26891099 |
A549 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 38.12 μM. |
26891099 |
bone marrow |
Function assay |
|
48 hrs |
Inhibition of RANKL-induced osteoclast differentiation in ICR mouse bone marrow cells after 48 hrs by TRAP assay, IC50 = 7.5 μM. |
26923696 |
U937 |
Function assay |
|
17 to 20 hrs |
Inhibition of LPS/IFN-gamma-induced PGE2 production in PMA-treated human U937 cells after 17 to 20 hrs by enzyme immunoassay, IC50 = 1.88 μM. |
27040659 |
RAW264.7 |
Function assay |
|
17 to 20 hrs |
Inhibition of LPS/IFN-gamma-induced PGE2 production in mouse RAW264.7 cells after 17 to 20 hrs by enzyme immunoassay, IC50 = 15.95 μM. |
27040659 |
BV2 |
Antiinflammatory assay |
|
24 hrs |
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay, IC50 = 4.77 μM. |
27228227 |
SH-SY5Y |
Neuroprotective assay |
|
24 hrs |
Neuroprotective activity in human SH-SY5Y cells assessed as reduction in 6-OHDA-induced cell death measured after 24 hrs by MTT assay, EC50 = 6.2 μM. |
27420919 |
PC3 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 24 hrs by MTT assay, IC50 = 39 μM. |
27496212 |
DU145 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay, IC50 = 41 μM. |
27496212 |
4T1 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay, IC50 = 49.4 μM. |
27496212 |
T47D |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human T47D cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 30 μM. |
27517806 |
CHOK1 |
Growth inhibition assay |
|
72 hrs |
Growth inhibition of CHOK1 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay, IC50 = 7.5 μM. |
27521589 |
LNCAP |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against human LNCAP cells after 3 days by WST or trypan blue assay, IC50 = 13.61 μM. |
27543391 |
PC3 |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against human PC3 cells after 3 days by WST or trypan blue assay, IC50 = 25.43 μM. |
27543391 |
DU145 |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against human DU145 cells after 3 days by WST or trypan blue assay, IC50 = 26.23 μM. |
27543391 |
BV2 |
Function assay |
|
1 hr |
Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 1 hr before LPS stimulation measured after 24 hrs by Griess assay, IC50 = 1.42 μM. |
27592135 |
BV2 |
Function assay |
|
1 hr |
Inhibition of Src in mouse BV2 cells assessed as suppression of LPS-induced NO release preincubated for 1 hr followed by LPS addition measured after 24 hrs by Griess assay, IC50 = 2.2 μM. |
27617803 |
A549 |
Antiproliferative assay |
|
48 hrs |
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay, IC50 = 15.06 μM. |
27816267 |
MDA-MB-231 |
Antiproliferative assay |
|
48 hrs |
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 24.54 μM. |
27816267 |
DU145 |
Antiproliferative assay |
|
48 hrs |
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay, IC50 = 44.71 μM. |
27816267 |
EAhy926 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 24.6 μM. |
27843113 |
Caco2 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 38.3 μM. |
27843113 |
CHOK1 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 42 μM. |
27843113 |
NCI-H1650 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human NCI-H1650 cells measured after 72 hrs by MTT assay, IC50 = 20.7 μM. |
27886548 |
LLC |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse LLC cells measured after 72 hrs by MTT assay, IC50 = 24.7 μM. |
27886548 |
A549 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay, IC50 = 27.8 μM. |
27886548 |
K562 |
Function assay |
|
48 hrs |
Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by Presto blue assay, GI50 = 19.67 μM. |
27908756 |
K562 |
Antiproliferative assay |
|
48 hrs |
Antiproliferative activity against human K562 cells measured after 48 hrs by Presto blue assay, GI50 = 21.67 μM. |
27908756 |
H460 |
Function assay |
|
48 hrs |
Inhibition of P-gp in drug resistant human H460 cells assessed as reduction in cell viability measured after 48 hrs by sulforhodamine B assay, GI50 = 26 μM. |
27908756 |
NCI-H460 |
Antiproliferative assay |
|
48 hrs |
Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay, GI50 = 27.3 μM. |
27908756 |
Raji |
Function assay |
|
48 hrs |
Inhibition of TPA-induced EBV-early antigen activation in human Raji cells after 48 hrs by indirect immunofluorescence method, IC50 = 12.1 μM. |
27933896 |
BV2 |
Function assay |
|
24 hrs |
Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 24 hrs followed by LPS-stimulation after 24 hrs by Griess assay, IC50 = 2.36 μM. |
28032759 |
PC3 |
Antiproliferative assay |
|
48 hrs |
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay, IC50 = 12.22 μM. |
28038323 |
MDA-MB-231 |
Antiproliferative assay |
|
48 hrs |
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 15.81 μM. |
28038323 |
BT549 |
Antiproliferative assay |
|
48 hrs |
Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay, IC50 = 24.93 μM. |
28038323 |
HeLa |
Antiproliferative assay |
|
48 hrs |
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay, IC50 = 25.41 μM. |
28038323 |
DU145 |
Antiproliferative assay |
|
48 hrs |
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay, IC50 = 28.41 μM. |
28038323 |
BV2 |
Function assay |
|
30 mins |
Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 30 mins followed by LPS-stimulation after 24 hrs by Griess assay, IC50 = 4.5 μM. |
28055210 |
THP1 |
Function assay |
|
1 hr |
Inhibition of LPS-induced tissue factor procoagulant activity in human THP1 cells preincubated for 1 hr followed by LPS addition measured after 5 hrs using factor 10a chromogenic substrate in presence of prothrombin complex, IC50 = 0.01316 μM. |
28109788 |
BT474 |
Antiproliferative assay |
|
24 hrs |
Antiproliferative activity against HER2 positive human BT474 cells after 24 hrs by MTT assay, IC50 = 30.14 μM. |
28319780 |
MDA-MB-453 |
Antiproliferative assay |
|
24 hrs |
Antiproliferative activity against HER2 positive human MDA-MB-453 cells after 24 hrs by MTT assay, IC50 = 32.4 μM. |
28319780 |
MDA-MB-157 |
Antiproliferative assay |
|
24 hrs |
Antiproliferative activity against human MDA-MB-157 cells after 24 hrs by MTT assay, IC50 = 40.38 μM. |
28319780 |
SKBR3 |
Antiproliferative assay |
|
24 hrs |
Antiproliferative activity against HER2 positive human SKBR3 cells after 24 hrs by MTT assay, IC50 = 42.83 μM. |
28319780 |
MCF7 |
Antiproliferative assay |
|
24 hrs |
Antiproliferative activity against ER/PR positive human MCF7 cells after 24 hrs by MTT assay, IC50 = 42.89 μM. |
28319780 |
MDA-MB-468 |
Antiproliferative assay |
|
24 hrs |
Antiproliferative activity against human MDA-MB-468 cells after 24 hrs by MTT assay, IC50 = 42.89 μM. |
28319780 |
T47D |
Antiproliferative assay |
|
24 hrs |
Antiproliferative activity against ER/PR positive human T47D cells after 24 hrs by MTT assay, IC50 = 47.91 μM. |
28319780 |
PWR-1E |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against human PWR-1E cells after 3 days by WST-1 assay, IC50 = 8.14 μM. |
28388523 |
LNCAP |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay, IC50 = 13.61 μM. |
28388523 |
PC3 |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay, IC50 = 25.43 μM. |
28388523 |
DU145 |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay, IC50 = 26.23 μM. |
28388523 |
BV2 |
Antineuroinflammatory assay |
|
15 mins |
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 15 mins followed by LPS-stimulation measured after 24 hrs by colorimetric method, IC50 = 6 μM. |
28514148 |
L428 |
Function assay |
|
2 hrs |
Inhibition of NF-kappaB (unknown origin) expressed in human L428 cells after 2 hrs by luciferase reporter gene assay |
28526369 |
PWR-1E |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against human PWR-1E cells expressing androgen receptor and PSA assessed as decrease in cell viability after 3 days by WST assay, IC50 = 8.85 μM. |
28601720 |
LNCAP |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against human LNCAP cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 13.61 μM. |
28601720 |
PC3 |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against human PC3 cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 25.43 μM. |
28601720 |
DU145 |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against human DU145 cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 26.23 μM. |
28601720 |
MDA-MB-231 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 12 μM. |
28654265 |
HT-29 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 14 μM. |
28654265 |
NCI-H460 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 15 μM. |
28654265 |
LN229 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 15 μM. |
28654265 |
U87 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 16 μM. |
28654265 |
COLO201 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 18 μM. |
28654265 |
A549 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 18 μM. |
28654265 |
T47D |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 19 μM. |
28654265 |
MML1 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human MML1 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 19 μM. |
28654265 |
BxPC3 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 29 μM. |
28654265 |
SK-MEL-2 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 36 μM. |
28654265 |
HCT116 |
Antiproliferative assay |
|
48 hrs |
Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay, GI50 = 3.5 μM. |
28716495 |
HCT116 |
Function assay |
|
48 hrs |
Induction of mitochondrial membrane potential loss in human HCT116 cells at antiproliferative GI50 after 48 hrs by JC-1 staining based fluorescence assay |
28716495 |
HCT116 |
Function assay |
|
60 mins |
Induction of mitochondrial superoxide generation in human HCT116 cells at antiproliferative GI50 after 60 mins by mitoSOX red-probe based fluorescence assay |
28716495 |
HCT116 |
Function assay |
|
60 mins |
Induction of reactive oxygen species generation in human HCT116 cells at antiproliferative GI50 after 60 mins by DCFH-DA probe based assay |
28716495 |
MCF7 |
Function assay |
|
48 hrs |
Modulation activity at ER in human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50 = 48 μM. |
28797797 |
BV2 |
Antiinflammatory assay |
|
24 hrs |
Antiinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay, IC50 = 4 μM. |
29035525 |
NCI-H460 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50 = 17.14 μM. |
29174816 |
PC3 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50 = 18.71 μM. |
29174816 |
DU145 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50 = 33.12 μM. |
29174816 |
HepG2 |
Function assay |
|
5 hrs |
Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay, EC50 = 21 μM. |
29223100 |
BGC823 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human BGC823 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 19.5 μM. |
29288946 |
NCI-H460 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 20.3 μM. |
29288946 |
SGC7901 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human SGC7901 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 26.2 μM. |
29288946 |
HepG2 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 13.78 μM. |
29421568 |
THP1 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 22.54 μM. |
29421568 |
K562 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 23.12 μM. |
29421568 |
LO2 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 25.67 μM. |
29421568 |
HeLa |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 31.89 μM. |
29421568 |
NCI-H460 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50 = 17.11 μM. |
29429834 |
PC3 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50 = 18.65 μM. |
29429834 |
DU145 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50 = 33.15 μM. |
29429834 |
MCF7 |
Cytotoxicity assay |
|
4 hrs |
Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay, IC50 = 22.1 μM. |
29605808 |
WRL68 |
Cytotoxicity assay |
|
4 hrs |
Cytotoxicity against human WRL68 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay, IC50 = 27.8 μM. |
29605808 |
A549 |
Cytotoxicity assay |
|
4 hrs |
Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay, IC50 = 43.9 μM. |
29605808 |
NCI-H1975 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 1.4 μM. |
29655083 |
A549 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 6.8 μM. |
29655083 |
HL7702 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 7.2 μM. |
29655083 |
H460 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 8.5 μM. |
29655083 |
NCI-H1650 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 20.5 μM. |
29655083 |
HepG2 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 10 μM. |
29798827 |
HCT116 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay, IC50 = 10.91 μM. |
29886021 |
HepG2 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 16.01 μM. |
29909338 |
SMMC7721 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 19.47 μM. |
29909338 |
QGY7703 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 21.44 μM. |
29909338 |
HHL5 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human HHL5 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 22.27 μM. |
29909338 |
LO2 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 23.87 μM. |
29909338 |
HT22 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against mouse HT22 cells assessed as reduction in cell viability after 24 hrs by MTT assay, MNTD = 1 μM. |
30031653 |
LNCAP |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against androgen-sensitive human LNCAP cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 13.61 μM. |
30121214 |
PC3 |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against androgen-insensitive human PC3 cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 25.43 μM. |
30121214 |
DU145 |
Antiproliferative assay |
|
3 days |
Antiproliferative activity against androgen-insensitive human DU145 cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 26.23 μM. |
30121214 |
MCF7 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay, IC50 = 9.8 μM. |
30138803 |
EJ28 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human EJ28 cells after 72 hrs by MTT assay, IC50 = 10.5 μM. |
30138803 |
HT1080 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay, IC50 = 13.1 μM. |
30138803 |
SW620 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human SW620 cells after 72 hrs by MTT assay, IC50 = 14 μM. |
30138803 |
A549 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 17.9 μM. |
30138803 |
SMMC7721 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 16.68 μM. |
30771605 |
HepG2 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 17.37 μM. |
30771605 |
LO2 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 22.69 μM. |
30771605 |
QGY7703 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 23.91 μM. |
30771605 |
HHL5 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against human HHL5 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 24.19 μM. |
30771605 |
HCT-116 |
Function assay |
|
24 hrs |
Inhibition of chymotrypsin-like activity of human 26S proteasome in human HCT-116 cells assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 24 hrs followed by addition of substrate and measured after 2 hrs by fluorometr, IC50 = 10 μM. |
30776692 |
SW480 |
Function assay |
|
24 hrs |
Inhibition of chymotrypsin-like activity of human 26S proteasome in human SW480 cells assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 24 hrs followed by addition of substrate and measured after 2 hrs by fluorometric, IC50 = 10 μM. |
30776692 |
RAW264.7 |
Function assay |
|
0.5 hrs |
Inhibition of MAPK/NFkappaB in ICR mouse RAW264.7 cells assessed as reduction in LPS-induced TNFalpha production pretreated for 0.5 hrs followed by LPS challenge and measured after 24 hrs by ELISA |
30780088 |
RAW264.7 |
Function assay |
|
0.5 hrs |
Inhibition of LPS-induced NFkappaB p65 nuclear translocation in ICR mouse RAW264.7 cells preincubated for 0.5 hrs followed by LPS challenge and measured after 40 mins by DAPI staining-based immunofluorescence microscopic analysis |
30780088 |
RAW264.7 |
Function assay |
|
0.5 hrs |
Inhibition of MAPK/NFkappaB in ICR mouse RAW264.7 cells assessed as reduction in LPS-induced IL6 production pretreated for 0.5 hrs followed by LPS challenge and measured after 24 hrs by ELISA |
30780088 |
RAW264.7 |
Function assay |
|
4 hrs |
Inhibition of RANKL-induced osteoclastogenesis in murine RAW264.7 cells assessed as formation of TRAP positive multinucleated osteoclasts pretreated for 4 hrs followed by RANKL addition measured after 72 hrs, IC50 = 3 μM. |
30794412 |
BV2 |
Antineuroinflammatory assay |
|
1 hr |
Anti-neuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by Griess reagent based assay, IC50 = 1.58 μM. |
31005056 |
SKOV3 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human SKOV3 Cells after 48 hrs by Cell Titer Blue assay, IC50 = 6.7 μM. |
31129455 |
U87MG |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human U87MG Cells 48 hrs by MTS assay, IC50 = 7.15 μM. |
31129455 |
LX2 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human LX2 Cells after 48 hrs by MTT assay, IC50 = 9.14 μM. |
31129455 |
MCF7 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human MCF7 Cells after 48 hrs by MTT assay, IC50 = 9.28 μM. |
31129455 |
HepG2 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human HepG2 Cells after 48 hrs by MTT assay, IC50 = 9.44 μM. |
31129455 |
3T3 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against mouse 3T3 Cells after 48 hrs by MTT assay, IC50 = 9.51 μM. |
31129455 |
MDA-MB-231 |
Anticancer assay |
|
72 hrs |
Anticancer activity against human MDA-MB-231 cells after 72 hrs by MTT assay, IC50 = 11.45 μM. |
31129455 |
SMMC7721 |
Anticancer assay |
|
72 hrs |
Anticancer activity against human SMMC7721 cells after 72 hrs by MTT assay, IC50 = 12.57 μM. |
31129455 |
LX2 |
Anticancer assay |
|
72 hrs |
Anticancer activity against human LX2 cells after 72 hrs by MTT assay, IC50 = 13.97 μM. |
31129455 |
SW480 |
Cytotoxicity assay |
|
24 to 48 hrs |
Cytotoxicity against human SW480 Cells after 24 to 48 hrs by MTT assay, IC50 = 15 μM. |
31129455 |
U251MG |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human U251MG cells after 48 hrs by MTS assay, IC50 = 15.26 μM. |
31129455 |
EAhy926 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human EAhy926 Cells after 72 hrs by MTT assay, IC50 = 20 μM. |
31129455 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human HepG2 Cells after 72 hrs by MTT assay, IC50 = 20.3 μM. |
31129455 |
CHOK1 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human CHOK1 Cells after 72 hrs by MTT assay, IC50 = 21.3 μM. |
31129455 |
HT-29 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human HT-29 Cells after 72 hrs by MTT assay, IC50 = 23.4 μM. |
31129455 |
A549 |
Cytotoxicity assay |
|
24 to 48 hrs |
Cytotoxicity against human A549 Cells after 24 to 48 hrs by MTT assay, IC50 = 28 μM. |
31129455 |
Caco2 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human Caco2 Cells after 72 hrs by MTT assay, IC50 = 28 μM. |
31129455 |
MDCK2 |
Cytotoxicity assay |
|
15 mins |
Cytotoxicity against mitoxantrone resistant human MDCK2 cells expressing BCRP after 15 mins by fluorescence assay, IC50 = 32 μM. |
31129455 |
K562 |
Cytotoxicity assay |
|
24 to 48 hrs |
Cytotoxicity against human K562 Cells after 24 to 48 hrs by MTT assay, IC50 = 36 μM. |
31129455 |
GBM1 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human GBM1 Cells 48 hrs by MTS assay, IC50 = 39.65 μM. |
31129455 |
PC12 |
Cytotoxicity assay |
|
24 hrs |
Cytotoxicity against rat PC12 cells measured after 24 hrs by WST8/PMS assay, CC50 = 42 μM. |
31262559 |
HCT116 |
Antiproliferative assay |
|
72 hrs |
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay, IC50 = 10.5 μM. |
31326241 |
KM12 |
Cytotoxicity assay |
|
4 hrs |
Cytotoxicity against human KM12 cells after 4 hrs by MTT assay, IC50 = 16 μM. |
31336310 |
SW480 |
Cytotoxicity assay |
|
4 hrs |
Cytotoxicity against human SW480 cells after 4 hrs by MTT assay, IC50 = 17.94 μM. |
31336310 |
HT-29 |
Cytotoxicity assay |
|
4 hrs |
Cytotoxicity against human HT-29 cells after 4 hrs by MTT assay, IC50 = 20.73 μM. |
31336310 |
WiDr |
Cytotoxicity assay |
|
4 hrs |
Cytotoxicity against human WiDr cells after 4 hrs by MTT assay, IC50 = 26.82 μM. |
31336310 |
SW116 |
Cytotoxicity assay |
|
4 hrs |
Cytotoxicity against human SW116 cells after 4 hrs by MTT assay, IC50 = 27.46 μM. |
31336310 |
Colon 26 |
Cytotoxicity assay |
|
4 hrs |
Cytotoxicity against mouse Colon 26 cells after 4 hrs by MTT assay, IC50 = 30.34 μM. |
31336310 |
PC3 |
Antiproliferative assay |
|
48 hrs |
Antiproliferative activity human PC3 cells assessed as reduction in Ki67 protein level at GI50 incubated for 48 hrs by DAPI staining based immunofluorescence assay |
31767266 |
22Rv1 |
Antiproliferative assay |
|
48 hrs |
Antiproliferative activity human 22Rv1 cells assessed as reduction in Ki67 protein level at GI50 incubated for 48 hrs by DAPI staining based immunofluorescence assay |
31767266 |
Sf21 |
Function assay |
|
10 mins |
Inhibition of recombinant human full-length His6-tagged p300 expressed in baculovirus infected Sf21 insect cells using [3H]acetylCoA as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by liquid scintillation co, IC50 = 25 μM. |
31910017 |
COS7 |
Function assay |
|
10 mins |
Inhibition of rabbit SERCA1b expressed in COS7 cells microsomal membranes preincubated for 10 mins followed by addition of ATP and measured after 40 mins by ELISA method, Ki = 5.8 μM. |
32030976 |
COS7 |
Function assay |
|
10 mins |
Inhibition of human SERCA3a expressed in COS7 cells microsomal membranes preincubated for 10 mins followed by addition of ATP and measured after 40 mins by ELISA method, Ki = 8.6 μM. |
32030976 |
A549 |
Function assay |
|
15 mins |
Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis, IC50 = 0.2 μM. |
ChEMBL |
RAW264.7 |
Function assay |
|
20 hrs |
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 20 hrs by griess assay, IC50 = 0.8 μM. |
ChEMBL |
MDCK |
Antiviral assay |
|
40 hrs |
Antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 40 hrs by CellTiter-Glo assay, IC50 = 6.7 μM. |
ChEMBL |
MDCK |
Antiviral assay |
|
40 hrs |
Antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 40 hrs by CellTiter-Glo assay, IC50 = 6.7 μM. |
ChEMBL |
RAW264.7 |
Antiinflammatory assay |
|
17 hrs |
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFN-gamma-stimulated nitric oxide production after 17 hrs by Griess assay, IC50 = 14.7 μM. |
ChEMBL |
MDCK |
Cytotoxicity assay |
|
40 hrs |
Cytotoxicity against MDCK cells assessed as decrease in cell viability after 40 hrs by CellTiter-Glo assay, CC50 = 48.3 μM. |
ChEMBL |
MDCK |
Cytotoxicity assay |
|
40 hrs |
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 40 hrs by CellTiter-Glo assay, CC50 = 48.3 μM. |
ChEMBL |
Caco2 |
Antiproliferative assay |
|
|
Antiproliferative activity against human Caco2 cells, IC50 = 10.3 μM. |
26539626 |
T67 |
Neuroprotective assay |
|
|
Neuroprotective effect in human T67 cells assessed as increase in NQO1 activity using DCIP as substrate |
26696252 |
HepG2 |
Cytotoxicity assay |
|
|
Cytotoxicity activity against human HepG2 cells by MTT assay, IC50 = 4.43 μM. |
26873414 |
A549 |
Cytotoxicity assay |
|
|
Cytotoxicity against human A549 cells by MTT assay, IC50 = 23.54 μM. |
26873414 |
MCF7 |
Cytotoxicity assay |
|
|
Cytotoxicity against human MCF7 cells by MTT assay, IC50 = 46.25 μM. |
26873414 |
SKOV3 |
Cytotoxicity assay |
|
|
Cytotoxicity against human SKOV3 cells by MTT assay, IC50 = 49.85 μM. |
26873414 |
A549/CDDP |
Function assay |
|
|
Inhibition of thioredoxin reductase in human A549/CDDP cells by DTNB dye based microplate spectrophotometry, IC50 = 39.42 μM. |
26891099 |
A549 |
Function assay |
|
|
Inhibition of thioredoxin reductase in human A549 cells by DTNB dye based microplate spectrophotometry, IC50 = 40.56 μM. |
26891099 |
HCT116 |
Antiproliferative assay |
|
|
Antiproliferative activity against human HCT116 cells up to 72 hrs by MTT assay, IC50 = 13.77 μM. |
28319780 |
MDA-MB-231 |
Antiproliferative assay |
|
|
Antiproliferative activity against human MDA-MB-231 cells up to 72 hrs by MTT assay, IC50 = 16.23 μM. |
28319780 |
PC3 |
Antiproliferative assay |
|
|
Antiproliferative activity against human PC3 cells up to 72 hrs by MTT assay, IC50 = 18.8 μM. |
28319780 |
A549 |
Growth inhibition assay |
|
|
Growth inhibition of human A549 cells, IC50 = 23 μM. |
28814374 |
Vero |
Cytotoxicity assay |
|
|
Cytotoxicity against African green monkey Vero cells assessed as growth inhibition, CC50 = 36.8 μM. |
29920454 |
LNCAP |
Antiproliferative assay |
|
|
Antiproliferative activity against androgen-sensitive human LNCAP cells, IC50 = 2 μM. |
30121214 |
DU145 |
Antiproliferative assay |
|
|
Antiproliferative activity against androgen-insensitive human DU145 cells, IC50 = 2 μM. |
30121214 |
PC3 |
Antiproliferative assay |
|
|
Antiproliferative activity against androgen-insensitive human PC3 cells, IC50 = 2 μM. |
30121214 |
HeLa |
Anticancer assay |
|
|
Anticancer activity against human HeLa cells, IC50 = 4.33 μM. |
31129455 |
HL60 |
Cytotoxicity assay |
|
|
Cytotoxicity against human HL60 cells, IC50 = 6.3 μM. |
31129455 |
HSC4 |
Cytotoxicity assay |
|
|
Cytotoxicity against human HSC4 cells, IC50 = 7.1 μM. |
31129455 |
HSC2 |
Cytotoxicity assay |
|
|
Cytotoxicity against human HSC2 cells, IC50 = 7.8 μM. |
31129455 |
AGS |
Cytotoxicity assay |
|
|
Cytotoxicity against human AGS Cells, IC50 = 9.77 μM. |
31129455 |
HSC3 |
Cytotoxicity assay |
|
|
Cytotoxicity against human HSC3 cells, IC50 = 11 μM. |
31129455 |
HeLa |
Cytotoxicity assay |
|
|
Cytotoxicity against human HeLa Cells, IC50 = 14.03 μM. |
31129455 |
RWPE1 |
Cytotoxicity assay |
|
|
Cytotoxicity against human RWPE1 cells, IC50 = 15.62 μM. |
31129455 |
MCF7 |
Apoptosis assay |
|
|
Induction of apoptosis in human MCF7 cells, IC50 = 17.1 μM. |
31129455 |
BGC823 |
Cytotoxicity assay |
|
|
Cytotoxicity against human BGC823 cells, IC50 = 17.5 μM. |
31129455 |
BxPC3 |
Cytotoxicity assay |
|
|
Cytotoxicity against human BxPC3 cells, IC50 = 18.25 μM. |
31129455 |
HT-29 |
Cytotoxicity assay |
|
|
Cytotoxicity against human HT-29 Cells, IC50 = 18.74 μM. |
31129455 |
H1299 |
Cytotoxicity assay |
|
|
Cytotoxicity against human H1299 cells, IC50 = 18.93 μM. |
31129455 |
PC3 |
Cytotoxicity assay |
|
|
Cytotoxicity against human PC3 cells, IC50 = 19.98 μM. |
31129455 |
AGS |
Cytotoxicity assay |
|
|
Cytotoxicity against human AGS Cells by MTT assay, IC50 = 20.76 μM. |
31129455 |
PC3 |
Anticancer assay |
|
|
Anticancer activity against human PC3 cells, IC50 = 20.9 μM. |
31129455 |
MGC803 |
Cytotoxicity assay |
|
|
Cytotoxicity against human MGC803 cells, IC50 = 21.2 μM. |
31129455 |
Hep2 |
Cytotoxicity assay |
|
|
Cytotoxicity against human Hep2 Cells, IC50 = 21.37 μM. |
31129455 |
MCF7 |
Cytotoxicity assay |
|
|
Cytotoxicity against human MCF7 cells, IC50 = 22.5 μM. |
31129455 |
SGC7901 |
Cytotoxicity assay |
|
|
Cytotoxicity against human SGC7901 cells, IC50 = 22.5 μM. |
31129455 |
A549 |
Cytotoxicity assay |
|
|
Cytotoxicity against human A549 Cells by MTT assay, IC50 = 25.33 μM. |
31129455 |
MDA-MB-231 |
Cytotoxicity assay |
|
|
Cytotoxicity against human MDA-MB-231 cells, IC50 = 26.5 μM. |
31129455 |
GES-1 |
Cytotoxicity assay |
|
|
Cytotoxicity against human GES-1 cells, IC50 = 29.1 μM. |
31129455 |
DU145 |
Anticancer assay |
|
|
Anticancer activity against human DU145 cells, IC50 = 31.7 μM. |
31129455 |
HL-7702 |
Cytotoxicity assay |
|
|
Cytotoxicity against human HL-7702 cells, IC50 = 32.33 μM. |
31129455 |
HepG2 |
Cytotoxicity assay |
|
|
Cytotoxicity against human HepG2 Cells, IC50 = 36.77 μM. |
31129455 |
HeLa |
Cytotoxicity assay |
|
|
Cytotoxicity against human HeLa cells, IC50 = 8.2 μM. |
31336310 |
B16 |
Cytotoxicity assay |
|
|
Cytotoxicity against human B16 cells by MTT assay, IC50 = 8.5 μM. |
31336310 |
HT1080 |
Function assay |
|
|
Decrease in UPA expression in human HT1080 cells, IC50 = 10 μM. |
31336310 |
Hep3B |
Cytotoxicity assay |
|
|
Cytotoxicity against human Hep3B cells, IC50 = 10 μM. |
31336310 |
BT474 |
Cytotoxicity assay |
|
|
Cytotoxicity against human BT474 cells, IC50 = 11 μM. |
31336310 |
T47D |
Cytotoxicity assay |
|
|
Cytotoxicity against human T47D cells, IC50 = 11 μM. |
31336310 |
HaCaT |
Cytotoxicity assay |
|
|
Cytotoxicity against human HaCaT cells, IC50 = 13 μM. |
31336310 |
HPL1D |
Cytotoxicity assay |
|
|
Cytotoxicity against human HPL1D cells, IC50 = 16 μM. |
31336310 |
MCF7 |
Cytotoxicity assay |
|
|
Cytotoxicity against human MCF7 cells, IC50 = 19.9 μM. |
31336310 |
22Rv1 |
Function assay |
|
|
Inhibition of NFkappaB p65 nuclear translocation in human 22Rv1 cells at GI50 by DAPI staining based immunofluorescence assay |
31767266 |
PC3 |
Function assay |
|
|
Inhibition of NFkappaB p65 nuclear translocation in human PC3 cells at GI50 by DAPI staining based immunofluorescence assay |
31767266 |
PC3 |
Function assay |
|
|
Inhibition of NFkappaB p65 transcriptional activity in human PC3 cells at GI50 by sandwich ELISA |
31767266 |
22Rv1 |
Function assay |
|
|
Inhibition of NFkappaB p65 transcriptional activity in human 22Rv1 cells at GI50 by sandwich ELISA |
31767266 |
HEK293T |
Cytotoxicity assay |
|
|
Cytotoxicity against HEK293T cells, IC50 = 15.2 μM. |
ChEMBL |
J774.1 |
Cytotoxicity assay |
|
|
Cytotoxicity against mouse J774.1 cells, IC50 = 31 μM. |
ChEMBL |